BTX BioTime Inc.

1.13
0  0%
Previous Close 1.13
Open 1.16
Price To Book 1.04
Market Cap 169096433
Shares 149,642,861
Volume 361,013
Short Ratio 12.47
Av. Daily Volume 745,698

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due 2019 and 2020.
AST-VAC2
Non-small cell lung cancer (NSCLC)
Phase 1/2 12-month data from cohorts 3 and 4 released July 31, 2018. Intends to meet with FDA regarding next steps.
AST-OPC1 SCiSTAR
Cervical spinal cord injury
Phase 1/2 enrolment to be completed 2019.
OpRegen
Dry age-related macular degeneration (AMD)

Latest News

  1. Edited Transcript of BTX earnings conference call or presentation 9-May-19 8:30pm GMT
  2. Don't Sell Forbuild SA (WSE:BTX) Before You Read This
  3. BioTime (BTX) Q1 2019 Earnings Call Transcript
  4. Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1
  5. BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®
  6. BioTime (BTX) Tops Q1 Earnings and Revenue Estimates
  7. BioTime: 1Q Earnings Snapshot
  8. BioTime Reports First Quarter 2019 Financial Results and Provides Business Update
  9. BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury
  10. BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
  11. Will BioTime (BTX) Report Negative Q1 Earnings? What You Should Know
  12. BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting
  13. The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
  14. BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy and Repair Conference
  15. Did Changing Sentiment Drive BioTime's (NYSEMKT:BTX) Share Price Down A Worrying 58%?
  16. BioTime to Present Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)
  17. BioTime (BTX) Upgraded to Strong Buy: Here's What You Should Know
  18. Top Ranked Momentum Stocks to Buy for April 2nd
  19. Edited Transcript of BTX earnings conference call or presentation 14-Mar-19 8:30pm GMT
  20. BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019